Development of resistance of human immunodeficiency virus type 1 to dextran sulfate associated with the emergence of specific mutations in the envelope gp120 glycoprotein

Molecular Pharmacology

Volumn 52, Issue 1, 1997, Pages 98-104

  Esté, José A ^a,b,c   Schols, Dominique ^a   De Vreese, Karen ^a   Van Laethem, Kristel ^a   Vandamme, Anne Mieke ^a   Desmyter, Jan ^a   De Clercq, Erik ^a  

^a REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

^b Irsicaixa AIDS Research Institute   (Spain)

^c HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

DEXTRAN SULFATE; ENVELOPE PROTEIN; GLYCOPROTEIN GP 120; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY;

AMINO ACID SEQUENCE; ANTIBODY SPECIFICITY; ARTICLE; CROSS RESISTANCE; GENE DELETION; GENOME; HUMAN IMMUNODEFICIENCY VIRUS; PLANT GROWTH; PRIORITY JOURNAL; SITE DIRECTED MUTAGENESIS; VIRUS INFECTION;

EID: 0030754130     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: 10.1124/mol.52.1.98     Document Type: Article

References (39)

1. Baba, M., R. Snoeck, R. Pauwels, and E. De Clereq. Sulfated polysaccharides are potent and selective inhibitors of various enveloped viruses, including herpes simplex virus, cytomegalovirus, vesicular stomatitis virus, and human immunodeficiency virus. Antimicrob. Agents Chemother. 32:1742-1745 (1988).
2. + cells. Science (Washington D. C.) 240:646-648 (1988).
3. Schols, D., M. Baba, R. Pauwels, J. Desmyter, and E. De Clercq. Specific interaction of aurintricarboxylic acid with the human immunodeficiency virus/CD4 cell receptor. Proc. Natl. Acad. Sci. USA 86:3322-3326 (1989).
4. Callahan, L. N., M. Phelan, M. Mallison, and M. Norcross. Dextran sulfate blocks antibody binding to the principal neutralizing domain of human immunodeficiency virus type 1 without interfering with gp120-CD4 interactions. J. Virol. 65:1543-1550 (1991).
5. Skinner, M. A., A. J. Langlois, C. B. McDanal, J. S. McDougal, D. P. Bolognesi, and T. J. Matthews. Neutralizing antibodies to an immunodominant envelope sequence do not prevent gp120 binding to CD4. J. Virol. 62:4195-4200 (1988).
6. Parish, C. R., L. Low, H. S. Warren, and A. L. Cunningham. A polyanion binding site on the CD4 molecule: proximity to the HIV-gp120 binding region. J. Immunol. 145:1188-1195 (1990).
7. Meylan, P. R. A., R. Kornbluth, I. Zbinden, and D. D. Richman. Influence of host cell type and V3 loop of the surface glycoprotein on susceptibility of human immunodeficiency virus type 1 to polyanion compounds. Antimicrob. Agents Chemother. 38:2910-2916 (1994).
8. De Jong, J., A. de Ronde, W. Keulen, M. Termette, and J. Goudsmit. Minimal requirements for the human immunodeficiency virus type 1 V3 domain to support the syncytium-inducing phenotype: analysis by single amino acid substitution. J. Virol. 66:6777-6780 (1992).
9. De Clercq, E., N. Yamamoto, R. Pauwels, J. Balzarini, M. Witvrouw, K. De Vreese, Z. Debyser, B. Rosenwirth, P. Peichl, R. Datema, D. Thornton, R. Skerlj, F. Gaul, S. Padmanabhan, G. Bridger, G. Henson, and M. Abrams. Highly potent and selective inhibition of human immunodeficiency virus by the bicyclam derivative JM3100. Antimicrob. Agents Chemother. 38: 668-674 (1994).
10. De Vreese, K., D. Reymen, P. Griffin, A. Steinkasserer, G. Werner, G. J. Bridger, J. Esté, W. James, G. W. Henson, J. Desmyter, J. Anné, and E. De Clercq. The bicyclams, a new class of potent human immunodeficiency virus inhibitors, block viral entry after binding. Antiviral Res. 29:209-219 (1996).
11. De Vreese, K., V. Kofler-Mongold, C. Leutgeb, V. Weber, K. Vermeire, S. Schacht, J. Anné, E. De Clercq, R. Datema, and G. Werner. The molecular target of bicyclams, potent inhibitors of human immunodeficiency virus replication. J. Virol. 70:689-696 (1996).
12. Esté, J. A., K. De Vreese, M. Witvrouw, J.-C. Schmit, A.-M. Vandamme, J. Anné, J. Desmyter, G. W. Henson, G. Bridger, and E. De Clercq. Antiviral activity of the bicyclam JM3100 against drug-resistant strains of human immunodeficiency virus type 1. Antiviral Res. 29:297-307 (1996).
13. Okada, T., and M. E. Gurney. Single basic amino acid substitutions at position 302 and 320 in the V3 domain of HIV type 1 are not sufficient to alter the antiviral activity of dextran sulfate and heparin. AIDS Res. Hum. Retrovirus 11:571-575 (1995).
14. Bates, P. Chemokine receptors and HIV-1: an attractive pair? Cell 86:1-3 (1996).
15. Oberlin, E., A. Amara, F. Bachelerie, C. Bessia, J. L. Virelizier, F. Arezana-Seisdedos, O. Schwartz, J. M. Heard, I. Clark-Lewis, D. F. Legler, M. Loetscher, M. Baggiolini, and B. Moser. The CXC chemokine SDF-1 is the ligand for LESTR/fusin and prevents infection by T-cell-line-adapted HIV-1. Nature (Lond.) 382:833-835 (1996).
16. + T cells. Science (Washington D. C.) 270:1811-1815 (1995).
17. + cells is mediated by the chemokine receptor CC-CKR-5. Nature (Lond.) 381:667-673 (1996).
18. Bridger G. J., R. T. Skerlj, D. Thornton, S. Padmanabhan, S. A. Martellucci, G. W. Henson, M. J. Abrams, N. Yamamoto, K. De Vreese, R. Pauwels, and E. De Clercq. Synthesis and structure-activity relationship of phenylenebis-(methylene)-linked bis-tetraazamacrocycles that inhibit HIV replication: effect of macrocyclic ring size and substituents on the aromatic linker. J. Med. Chem. 38:366-378 (1995).
19. Yamamoto, N., D. Schols, E. De Clercq, Z. Debyser, R. Pauwels, J. Balzarini, H. Nakashima, M. Baba, M. Hosoya, R. Snoeck, J. Neyts, G. Andrei, B. A. Murrer, B. Theobald, G. Bossard, G. Henson, M. Abrams, and D. Picker. Mechanism of anti-human immunodeficiency virus action of polyoxometalates, a class of broad-spectrum antiviral agents. Mol. Pharmacol. 42:1109-1117 (1992).
20. Pauwels, R., K. Andries, J. Desmyter, D. Schols, M. Kukla, H. Breslin, A. Raeymaeckers, J. Van Gelder, R. Woestenborghs, J. Heykants, K. Schellekens, M. Janssen, E. De Clercq, and P. Janssen. Potent and selective inhibition of HIV-1 replication in vitro by a novel series of TIBO derivatives. Nature (Lond.) 343:470-474 (1990).
21. Jansen, R. W., D. Schols, R. Pauwels, E. De Clercq, and D. F. K. Meijer. Novel, negatively charged human serum albumins display potent and selective in vitro anti-human immunodeficiency virus type 1 activity. Mol. Pharmacol. 44:1003-1007 (1993).
22. Ojwang, J. O., R. Buckheit, Y. Pommier, A. Mazunder, K. De Vreese, J. A. Esté, D. Reymen, L. Pallansch, C. Lackman-Smith, T. Wallace, E. De Clercq, M. McGrath, and R. F. Rando. T30177, an oligonuclotide stabilized by an intramolecular guanosine octet, is a potent inhibitor of laboratory strains and clinical isolates of human immunodeficiency virus type 1. Antimicrob. Agents Chemother. 39:2426-2435 (1995).
23. Pauwels, R., J. Balzarini, M. Baba, R. Snoeck, D. Schols, P. Herdewijn, J. Desmyter, and E. De Clercq. Rapid and automated tetrazolium-based colorimetric assay for the detection of anti-HIV compounds. J. Virol. Methods 20:309-321 (1988).
24. Witvrouw, M., J. A. Esté, M. Quiñones-Mateu, D. Reymen, G. Andrei, R. Snoeck, S. Ikeda, R. Pauwels, N. Bianchini, J. Desmyter, and E. De Clercq. Activity of a sulfated polysaccharide extracted from the red seaweed Aghardiella tenera against human immunodeficiency virus and other enveloped viruses. Antiviral Chem. Chemother. 5:297-303 (1994).
25. Datema, R., L. Rabin, M. Hincenberg, M. Beth, S. Warren, V. Linquist, B. Rosenwirth, J. Seifert, and J. M. McCune. Antiviral efficacy in vivo of the anti-human immunodeficiency virus bicyclam SDZ SID791 (JM3100), an inhibitor of infectious cell entry. Antimicrob. Agents Chemother. 40:750-754 (1996).
26. Callahan, L. N. HIV-1 virion-cell interactions: an electrostatic model of pathogenicity and syncytium formation. AIDS Res. Hum. Retrovirus 10: 231-233 (1994).
27. Roderiquez, G., T. Oravecz, M. Yanagishita, D. Bou-Habib, H. Mostowski, and M. A. Norcross. Mediation of human immunodeficiency virus type 1 binding by interaction of cell surface heparan sulfate proteoglycans with the V3 region of envelope gp120-gp41. J. Virol. 69:2233-2239 (1995).
28. Lin, P.-L., H. Samanta, C. Bechtolds, C. A. Deminie, A. K. Patick, M. Alam, K. Riccardi, R. E. Rose, R. J. White, and R. J. Colonno. Characterization of siamycin I, a human immunodeficiency virus fusion inhibitor. Antimicrob. Agents Chemother. 40:133-138 (1996).
29. Wild, C., T. Greenwell, D. Shugars, L. Rimsky-Clarke, and T. Matthews. The inhibitory activity of an HIV type 1 peptide correlates with its ability to interact with a leucine zipper structure. AIDS Res. Hum. Retroviruses 11:323-325 (1996).
30. Cann, A. J., M. Churcher, M. Boyd, W. O'Brien, J.-Q. Zhao, J. Zack, and I. S. Y. Chen. The region of the envelope gene of human immunodeficiency virus type 1 responsible for the determination of cell tropism. J. Virol. 66:305-309 (1992).
31. Chesebro, B., K. Wehrly, J. Nishio, and S. Perryman. Macrophage-tropic human immunodeficiency virus isolates from different patients exhibit unusual V3 envelope sequence homogeneity in comparison with T-cell-tropic isolates: definition of critical amino acids involved in cell tropism. J. Virol. 66:6547-6554 (1992).
32. Hwang, S. S., T. J. Boyle, K. Lyerly, and B. R. Cullen. Identification of the envelope V3 loop as the primary determinant of cell tropism in HIV-1. Science (Washington D. C.) 253:71-74 (1991).
33. Shioda, T., J. A. Levy, and C. Cheng-Mayer. Macrophage and T cell-line tropism of HIV-1 are determined by specific regions of the envelope gp120 gene. Nature (Lond.) 349:167-169 (1991).
34. De Jong, J., J. Goudsmit, W. Keulen, B. Klaver, W. Krone, M. Tersmette, and A. de Ronde. Human immunodeficiency virus type 1 clones chimeric for the V3 domain differ in syncytium formation and replication capacity. J. Virol. 66:757-765 (1992).
35. Bhattacharyya, D., B. Brooks, and L. Callahan. Positioning of positively charged residues in the V3 loop correlates with HIV type 1 syncytium-inducing phenotype. AIDS Res. Hum. Retroviruses 12:83-90 (1996).
36. Bleul, C. C., M. Farzan, H. Choe, C. Parolin, I. Clark-Lewis, J. Sodroski, and T. A. Springer. The lymphocyte chemoattractant SDF-1 is a ligand for LESTR/fusin and blocks HIV-1 entry. Nature (Lond.) 382:829-832 (1996).
37. Schols, D., R. Pauwels, J. Desmyter, and E. De Clercq. Dextran sulfate and other polyanionic anti-HIV compounds specifically interact with the gp120 glycoprotein expressed by T-cells persistently infected with HIV-1. Virology 175:556-561 (1990).
38. Cushman, M., W. M. Golebiewski, Y. Pollier, A. Mazumder, D. Reymen, E. De Clercq, L. Graham, and W. G. Rice. Cosalane analogues with enhanced potencies as inhibitors of HIV-1 protease and integrase. J. Med. Chem. 38:443-452 (1995).
39. Gallaher, W. R., J. Ball, R. Garry, A. Martin-Amedee, and R. Montelaro. A general model for the surface glycoprotein of HIV and other retroviruses. AIDS Res. Hum. Retroviruses 11:191-202 (1992).